HMG CoA reductase inhibitors and impotence: Two case series from the Spanish and French drug monitoring systems

Drug Safety

Volumn 29, Issue 2, 2006, Pages 143-149

  Carvajal, Alfonso ^a,c   Macias, Diego ^a   Sáinz, María ^a   Ortega, Sara ^a   Arias, Luis H Martín ^a   Velasco, Alfonso ^a   Bagheri, Haleh ^b   Lapeyre Mestre, Maryse ^b   Montastruc, Jean Louis ^b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b Centre Régional de Pharmacovigilance Midi Pyrénées   (France)

^c Facultad de Medicina   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; DRUG WITHDRAWAL; HUMAN; HYPERLIPIDEMIA; IMPOTENCE; INFORMATION PROCESSING; MALE; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMPOTENCE; MALE; MIDDLE AGED; SPAIN;

EID: 32344434232     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200629020-00004     Document Type: Article

References (26)

1. Sweetman SC, editor. Martindale: the extra pharmacopoeia. 34th Edition. London: Pharmaceutical Press, 2005: 811
2. Walley T, Folino-Gallo P, Schwabe U, et al. Variations and increase in use of statins across Europe data from administrative databases. BMJ 2004; 328: 385-6
3. Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Study (4S). Lancet 1994; 344: 1383-9
4. Halkin A, Lossos IS, Mevaorach D. HMG-CoA reductase inhibitor-induced impotence [letter]. Ann Pharmacother 1996; 30: 192
5. Schneider J, Kaffarnik H. Impotence in patients treated with clofibrate. Atherosclerosis 1975; 21: 455-7
6. Pizzarro S, Bargay J, D'Agosto P. Gemfibrozil-induced impotence [letter]. Lancet 1990; 336: 1135
7. Bain SC, Lemon M, Jones AF. Gemfibrozil-induced impotence [letter]. Lancet 1990; 336: 1389
8. Bharani A. Sexual dysfunction after gemfibrozil [letter]. BMJ 1992; 305: 693
9. Figueras A, Castel JM, Laporte JR, et al. Gemfibrozil-induced impotence [letter]. Ann Pharmacother 1993; 27: 982
10. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977; 21: 247-54
11. World Health Organization. International Monitoring of Adverse Reactions to Drugs: Adverse Reaction Terminology. Uppsala: World Health Organization Collaborating Centre for International Drug Monitoring, 1992
12. Lunde PKM, Baksaas I, Halse M, et al. The methodology of drug utilization studies. In: Bergman U, Grimsson A, Wahba AHW, et al., editors. Studies in drug utilization. Copenhagen: World Health Organization Office for Europe, 1979: 17-28
13. World Health Organization Collaborating Centre for Drugs Statistics Methodology Anatomical therapeutic chemical (ATC) classification index with defined daily doses (DDDs). Oslo, Norway: World Health Organization Collaborating Centre for Drugs Statistics Methodology, 2005
14. Tubert P, B́egaud B, Ṕeŕe JC, et al. Power and weakness of spontaneous reporting: a probabilistic approach. J Clin Epidemiol 1992; 45: 283-6
15. Rothman KJ, Greenland S. Measures of disease frequency. In: Rothman KJ, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1998: 29-46
16. Dobson AJ, Kuulasmaa K, Ebrele E, et al. Confidence intervals for weight sums of poisson parameters. Stat Med 1991; 10: 452-7
17. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzime A-reductase inhibitors [statins]. Eur J Clin Pharmacol 2001; 57: 357-64
18. Jackson G. Simvastatin and impotence [letter]. BMJ 1997; 315: 31
19. Boyd IW. HMG-CoA reductase inhibitor-induced impotence [letter]. Ann Pharmacother 1996; 30: 1199
20. Adverse Drug Reactions Advisory Committee. Simvastatin and adverse endocrine effects in men. Aust Adverse Drug React Bull 1995; 14: 10
21. Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002; 19: 95-8
22. de Graaf L, Brouwers AH, Diemont WL. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors? Br J Clin Pharmacol 2004 Sep; 58 (3): 326-8
23. Pedersen TR, Faergeman O. Simvastatin seems unlikely to cause impotence [letter]. BMJ 1999; 318: 192
24. Bruckert E, Giral P, Heshmati HM, et al. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 1996; 21: 89-94
25. Azzarito C, Boiardi L, Vergoni W, et al. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res 1996 Apr; 28 (4): 193-8
26. Jay RH, Sturley RH, Stirling C, et al. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Clin Pharmacol 1991; 32: 417-22